Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
11 studies found for:    "Primary agammaglobulinemia"
Show Display Options
Rank Status Study
1 Completed A Study of the Safety and Efficacy of Vigam® Liquid in Patients With Primary or Secondary Antibody Deficiency
Condition: Primary or Secondary Antibody Deficiency (PAD or SAD).
Intervention: Biological: Vigam® (Human Normal Immunoglobulin)
2 Recruiting Polysaccharide Antibody Response Study
Condition: Specific Polysaccharide Antibody Deficiency
Interventions: Biological: Pneumovax 23 (Sanofi Pasteur MSD);   Biological: Typhim Vi (Sanofi Pasteur MSD)
3 Unknown  Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)
Conditions: Primary Immunodeficiency;   Agammaglobulinemia;   Hypogammaglobulinemia;   Antibody Deficiency
Intervention: Biological: Kedrion IVIG 10%
4 Completed Specific IgG Antibody in Patients With Primary Antibody Deficiencies Treated With Subcutaneous Immunoglobulin
Conditions: Common Variable Immunodeficiency;   Agammaglobulinemia
Intervention: Biological: gammaglobulin
5 Completed A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam®
Condition: Primary Antibody Deficiency.
Intervention: Biological: Subgam® (Human Normal Immunoglobulin Solution)
6 Active, not recruiting Construction of a Health-related Quality of Life (HR-QOL) Questionnaire for Patients With Primary Antibody Deficiency Disease
Condition: Immune Deficiency, Antibody
Intervention: Other: questionnaire survey
7 Unknown  Evaluate Bacteriophage as a Useful Immunogen in Patients With Primary Immune Deficiency Diseases (PIDD)
Condition: Primary Immune Deficiency Diseases
Intervention: Biological: Bacteriophage OX174
8 Completed
Has Results
Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)
Condition: Primary Immune Deficiency Disorders (PIDD)
Intervention: Biological: Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]
9 Completed A Clinical Study of Intravenous Immunoglobulin
Condition: Immunologic Deficiency Syndromes
Intervention: Drug: Immune Globulin Intravenous (Human) Omr-IgG-am IGIV
10 Completed
Has Results
Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.
Conditions: Primary Immunodeficiency;   Common Variable Hypogammaglobulinemia;   X-linked Hypogammaglobulinemia;   Hypogammaglobulinemia;   Immunodeficiency With Hyper-IgM;   Wiskott-Aldrich Syndrome
Intervention: Biological: Gammaplex (Intravenous immunoglobulin)
11 Completed Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)
Condition: Primary Immunodeficiency Disorders
Intervention: Biological: RI-002

Indicates status has not been verified in more than two years